Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3235-3239

  Worzalla, John F ^a   Shih, Chuan ^a   Schultz, Richard M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antifolate; Antitumor activity; Folic acid; LY231514

Indexed keywords

FOLIC ACID; FOLIC ACID ANTAGONIST; PEMETREXED;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DIETARY INTAKE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LETHALITY; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; FOLIC ACID; FOLIC ACID DEFICIENCY; GLUTAMATES; GUANINE; HUMANS; LETHAL DOSE 50; LEUKEMIA L5178; MICE; MICE, INBRED DBA; MICE, NUDE; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0031730802     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, Jannatipour M and Moran RG: A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-{4-[2-(2-amino-1,7dihydro-4-oxopyrrolo [2,3-d]pyrimidine-6-yl)ethyl]benzoyl} glutamic acid, a new and potent inhibitor of thymidylate synthase. J Med Chem 35: 4450-4454, 1992.
2. Grindey GB, Shih C, Barnett CJ, Pearce HL, Engelhardt JA, Todd, GC, Rinzel SM, Worzalla JF, Gossett LS and Everson TP: LY231514, a novel pyrrolopyrimldine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res 33: 411, 1992.
3. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M and Schultz RM: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123, 1997.
4. Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langley C, Clark G, Faries D, Lu P and Van Hoff DD: Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13: 2842-2850, 1995.
5. Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG and Grindey GB: Augmentation of the therapeutic activity of lometrexol [(6-R)5,10-dideazatetrahydrofolate] by oral folic acid. Cancer Res 56: 2331-2335, 1996.
6. Mendelsohn LG, Gates SB, Habeck LL, Shackelford KA, Worzalla J, Shih C and Grindey GB: The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol. Advan Enzyme Regul 36: 365-381, 1996.
7. Smith GK, Amyx H, Boytos CM, Duch DS, Ferone R and Wilson HR: Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res 55: 6117-6125, 1995.
8. Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW and Moran RG: Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 85: 1154-1159, 1993.
9. Laohavinij S, Wedge SR, Lind MJ, Bailey N, Humphreys A, Proctor M, Chapman F, Simmons D, Oakley A, Robson L, Gumbrell L, Taylor GA, Thomas HD, Boddy AV, Newell DR and Calvert AH: A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Invest New Drugs 14: 325-335, 1996.
10. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL and Alarcon GS: The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 33: 9-18, 1990.
11. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
12. Worzalla JF, Bewley JR and Grindey GB: Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer. Invest New Drugs 8: 241-251, 1990.
13. Schmitz JC, Grindey GB, Schultz RM and Priest DG: Impact of dietary folic acid on reduced folates in mouse plasma and tissues: relationship to dideazatetrahydrofolate sensitivity. Biochem Pharmacol 48: 319-325, 1992.
14. Duch DS, Banks SD, Dev IK, Dickerson SJ, Ferone R, Heath LS, Humphreys J, Knick V, Pendergast W, Singer S, Smith GK, Waters K and Wilson HR: Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 53: 810-818, 1993.
15. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR and Hughes LR: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 cell growth In vitro and in vivo; a new agent for clinical study. Cancer Res 51: 5579-5586, 1991.
16. Pohland RC, Alati T, Lantz RJ and Grindey GB: Whole-body autoradiographic disposition and plasma pharmacokinetics of 5,10-dideazatetrahydrofolic acid in mice fed folic acid-deficient or regular diets. J Pharm Sci 83: 1396-1399, 1994.
17. Antony AC: The biological chemistry of folate receptors. Blood 79: 2807-2820, 1992.
18. Schultz RM, Andis SL, Shackelford KA, Gates SB, Ratnam M, Mendelsohn LG, Shih C and Grindey GB: Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells. Oncology Res 7: 97-102, 1995.